NCT03500627View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

July 20, 2018

Study Completion Date

July 20, 2018

Conditions
Healthy
Interventions
DRUG

OP-101

Intravenous Injection of OP-101 in healthy volunteers.

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors

Lead Sponsor

Orpheris, Inc.
All Listed Sponsors
lead

Orpheris, Inc.

INDUSTRY